The workshop was convened on September 27, 2013 chaired by Dr. George Daley and included expert presentations on stem cell biology and differentiation, cell processing, transfusion medicine, and the development of stem cell-derived red blood cell, platelet, and myeloid progenitor products. In addition, representatives from biotechnology firms, BARDA, FDA, the Army Blood Bank, the NIH Center for Regenerative Medicine, and the California Institute of Regenerative Medicine were present and made important contributions to the discussions. The workshop participants identified areas where NHLBI support is needed to address remaining research questions both in the basic arena and to enable translation through improved cell production and processing.

Recap

Challenges before us

The goal is to use stem cell technology to produce blood cells in vitro, such as hematopoietic stem cells, red blood cells, platelets, or granulocytes. This approach holds the promise of an abundant number of uniform cells with defined biological properties free of reactive antigens and infectious agents. With the current state of the science it is already possible to derive blood cells in the laboratory and stem cell-derived red blood cells have been safety tested in humans. What is required is to advance the remaining aspects of basic research and cell processing to enable clinical-grade manufacture in a feasible, cost-effective manner. Prior to use, a strategy for clinical assessment is required that includes both functional and safety measures. In the end, the true determinant of this new approach will be medical needs met and the range of uses it can fulfill.

Research needs

Molecular mechanisms of cellular heterogeneity; this can be addressed by single cell analysis